Literature DB >> 12768002

Determinants of increased replicative capacity of serially passaged simian immunodeficiency virus with nef deleted in rhesus monkeys.

Louis Alexander1, Petr O Illyinskii, Sabine M Lang, Robert E Means, Jeffrey Lifson, Keith Mansfield, Ronald C Desrosiers.   

Abstract

Most rhesus macaques infected with simian immunodeficiency virus SIVmac239 with nef deleted (either Delta nef or Delta nef Delta vpr Delta US [Delta 3]) control viral replication and do not progress to AIDS. Some monkeys, however, develop moderate viral load set points and progress to AIDS. When simian immunodeficiency viruses (SIVs) recovered from two such animals (one Delta nef and the other Delta 3) were serially passaged in rhesus monkeys, the SIVs derived from both lineages were found to consistently induce moderate viral loads and disease progression. Analysis of viral sequences in the serially passaged derivatives revealed interesting changes in three regions: (i) an unusually high number of predicted amino acid changes (12 to 14) in the cytoplasmic domain of gp41, most of which were in regions that are usually conserved; these changes were observed in both lineages; (ii) an extreme shortening of nef sequences in the region of overlap with U3; these changes were observed in both lineages; and (iii) duplication of the NF-kappa B binding site in one lineage only. Neither the polymorphic gp41 changes alone nor the U3 deletion alone appeared to be responsible for increased replicative capacity because recombinant SIVmac239 Delta nef, engineered to contain either of these changes, induced moderate viral loads in only one of six monkeys. However, five of six monkeys infected with recombinant SIVmac239 Delta nef containing both TM and U3 changes did develop persisting moderate viral loads. These genetic changes did not increase lymphoid cell-activating properties in the monkey interleukin-2-dependent T-cell line 221, but the gp41 changes did increase the fusogenic activity of the SIV envelope two- to threefold. These results delineate sequence changes in SIV that can compensate for the loss of the nef gene to partially restore replicative and pathogenic potential in rhesus monkeys.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12768002      PMCID: PMC156171          DOI: 10.1128/jvi.77.12.6823-6835.2003

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  70 in total

1.  Neutralization sensitivity of cell culture-passaged simian immunodeficiency virus.

Authors:  R E Means; T Greenough; R C Desrosiers
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

2.  Features of the SIVmac transmembrane glycoprotein cytoplasmic domain that are important for Env functions.

Authors:  B L Shacklett; C Denesvre; B Boson; P Sonigo
Journal:  AIDS Res Hum Retroviruses       Date:  1998-03-20       Impact factor: 2.205

3.  Resistance of neonatal monkeys to live attenuated vaccine strains of simian immunodeficiency virus.

Authors:  M S Wyand; K H Manson; A A Lackner; R C Desrosiers
Journal:  Nat Med       Date:  1997-01       Impact factor: 53.440

4.  Plasma SIV RNA viral load determination by real-time quantification of product generation in reverse transcriptase-polymerase chain reaction.

Authors:  K Suryanarayana; T A Wiltrout; G M Vasquez; V M Hirsch; J D Lifson
Journal:  AIDS Res Hum Retroviruses       Date:  1998-01-20       Impact factor: 2.205

5.  HIV-1 Nef protein protects infected primary cells against killing by cytotoxic T lymphocytes.

Authors:  K L Collins; B K Chen; S A Kalams; B D Walker; D Baltimore
Journal:  Nature       Date:  1998-01-22       Impact factor: 49.962

6.  Identification of highly attenuated mutants of simian immunodeficiency virus.

Authors:  R C Desrosiers; J D Lifson; J S Gibbs; S C Czajak; A Y Howe; L O Arthur; R P Johnson
Journal:  J Virol       Date:  1998-02       Impact factor: 5.103

7.  Vaccine protection by a triple deletion mutant of simian immunodeficiency virus.

Authors:  M S Wyand; K H Manson; M Garcia-Moll; D Montefiori; R C Desrosiers
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

8.  Requirements for lymphocyte activation by unusual strains of simian immunodeficiency virus.

Authors:  Z Du; P O Ilyinskii; V G Sasseville; M Newstein; A A Lackner; R C Desrosiers
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

9.  Temporal analyses of virus replication, immune responses, and efficacy in rhesus macaques immunized with a live, attenuated simian immunodeficiency virus vaccine.

Authors:  R I Connor; D C Montefiori; J M Binley; J P Moore; S Bonhoeffer; A Gettie; E A Fenamore; K E Sheridan; D D Ho; P J Dailey; P A Marx
Journal:  J Virol       Date:  1998-09       Impact factor: 5.103

10.  The HIV-1 nef protein interferes with phosphatidylinositol 3-kinase activation 1.

Authors:  A Graziani; F Galimi; E Medico; E Cottone; D Gramaglia; C Boccaccio; P M Comoglio
Journal:  J Biol Chem       Date:  1996-03-22       Impact factor: 5.157

View more
  37 in total

1.  A single amino acid mutation in the envelope cytoplasmic tail restores the ability of an attenuated simian immunodeficiency virus mutant to deplete mucosal CD4+ T cells.

Authors:  Matthew W Breed; Andrea P O Jordan; Pyone P Aye; Chie Sugimoto; Xavier Alvarez; Marcelo J Kuroda; Bapi Pahar; Brandon F Keele; James A Hoxie; Andrew A Lackner
Journal:  J Virol       Date:  2013-09-11       Impact factor: 5.103

2.  Nef alleles from human immunodeficiency virus type 1-infected long-term-nonprogressor hemophiliacs with or without late disease progression are defective in enhancing virus replication and CD4 down-regulation.

Authors:  Andrea Crotti; Francesca Neri; Davide Corti; Silvia Ghezzi; Silvia Heltai; Andreas Baur; Guido Poli; Elena Santagostino; Elisa Vicenzi
Journal:  J Virol       Date:  2006-08-30       Impact factor: 5.103

3.  Transcriptional activity of blood-and cerebrospinal fluid-derived nef/long-terminal repeat sequences isolated from a slow progressor infected with nef-deleted human immunodeficiency virus type 1 (HIV-1) who developed HIV-associated dementia.

Authors:  Melissa J Churchill; Anna Figueiredo; Daniel Cowley; Lachlan Gray; Damian Fj Purcell; John S Sullivan; Dale A McPhee; Steven L Wesselingh; Bruce J Brew; Paul R Gorry
Journal:  J Neurovirol       Date:  2006-06       Impact factor: 2.643

4.  Longitudinal analysis of human immunodeficiency virus type 1 nef/long terminal repeat sequences in a cohort of long-term survivors infected from a single source.

Authors:  Melissa J Churchill; David I Rhodes; Jennifer C Learmont; John S Sullivan; Steven L Wesselingh; Ian R C Cooke; Nicholas J Deacon; Paul R Gorry
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

5.  A combination DNA and attenuated simian immunodeficiency virus vaccine strategy provides enhanced protection from simian/human immunodeficiency virus-induced disease.

Authors:  Rama Rao Amara; Kalpana Patel; Genevieve Niedziela; Pragati Nigam; Sunita Sharma; Silvija I Staprans; David C Montefiori; Lakshmi Chenareddi; James G Herndon; Harriet L Robinson; Harold M McClure; Francis J Novembre
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

6.  Human endothelial cells enhance human immunodeficiency virus type 1 replication in CD4+ T cells in a Nef-dependent manner in vitro and in vivo.

Authors:  Jaehyuk Choi; Jason Walker; Sergei Boichuk; Nancy Kirkiles-Smith; Nicholas Torpey; Jordan S Pober; Louis Alexander
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

7.  Relative replication capacity of phenotypic SIV variants during primary infections differs with route of inoculation.

Authors:  Tasha Biesinger; Robert White; Monica T Yu Kimata; Brenda K Wilson; Jonathan S Allan; Jason T Kimata
Journal:  Retrovirology       Date:  2010-10-13       Impact factor: 4.602

Review 8.  The tale of the long tail: the cytoplasmic domain of HIV-1 gp41.

Authors:  Thomas S Postler; Ronald C Desrosiers
Journal:  J Virol       Date:  2012-10-17       Impact factor: 5.103

9.  Loss of a tyrosine-dependent trafficking motif in the simian immunodeficiency virus envelope cytoplasmic tail spares mucosal CD4 cells but does not prevent disease progression.

Authors:  Matthew W Breed; Andrea P O Jordan; Pyone P Aye; Cornelis F Lichtveld; Cecily C Midkiff; Faith R Schiro; Beth S Haggarty; Chie Sugimoto; Xavier Alvarez; Netanya G Sandler; Daniel C Douek; Marcelo J Kuroda; Bapi Pahar; Michael Piatak; Jeffrey D Lifson; Brandon F Keele; James A Hoxie; Andrew A Lackner
Journal:  J Virol       Date:  2012-11-14       Impact factor: 5.103

10.  Immunization with single-cycle SIV significantly reduces viral loads after an intravenous challenge with SIV(mac)239.

Authors:  Bin Jia; Sharon K Ng; M Quinn DeGottardi; Michael Piatak; Eloísa Yuste; Angela Carville; Keith G Mansfield; Wenjun Li; Barbra A Richardson; Jeffrey D Lifson; David T Evans
Journal:  PLoS Pathog       Date:  2009-01-23       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.